Inovio Faces Deadline for Shareholder Lawsuit

Rosen Law Firm urges Inovio Pharmaceuticals to respond to class action filing by today's deadline.

Apr. 7, 2026 at 5:27pm

Got story updates? Submit your updates here. ›

A close-up photograph of a single syringe filled with a clear liquid, resting on a plain white background. The syringe is the sole focus, casting a sharp shadow and using dramatic lighting to symbolize the high stakes and scrutiny surrounding the development of a COVID-19 vaccine.A single syringe filled with a clear liquid stands alone, symbolizing the high-stakes pressure on pharmaceutical companies to deliver effective COVID-19 vaccines.NYC Today

Inovio Pharmaceuticals, a biotechnology company focused on developing DNA medicines, is facing a deadline today to respond to a class action lawsuit filed by shareholders. The Rosen Law Firm, which is representing the plaintiffs, is urging Inovio to address the allegations before the court-imposed deadline expires.

Why it matters

The shareholder lawsuit alleges that Inovio made misleading statements about the progress of its COVID-19 vaccine candidate, which could have impacted investor confidence and stock price. The outcome of this case could have significant financial and reputational consequences for the company.

The details

The class action lawsuit was filed in the U.S. District Court for the Eastern District of Pennsylvania in 2025, accusing Inovio of making false and misleading statements about the development timeline and clinical trial results for its COVID-19 vaccine candidate. The plaintiffs claim these statements artificially inflated Inovio's stock price, leading to losses when the truth was revealed.

  • The lawsuit was filed in the U.S. District Court for the Eastern District of Pennsylvania in 2025.
  • Inovio has until the end of today, April 7, 2026, to respond to the lawsuit.

The players

Inovio Pharmaceuticals

A biotechnology company focused on developing DNA medicines, including a COVID-19 vaccine candidate.

Rosen Law Firm

A law firm representing the plaintiffs in the class action lawsuit against Inovio.

Got photos? Submit your photos here. ›

What they’re saying

“We urge Inovio to take the necessary steps to address the allegations in the lawsuit before the court-imposed deadline.”

— Laurence Rosen, Managing Partner, Rosen Law Firm

What’s next

If Inovio fails to respond to the lawsuit by the deadline, the court could issue a default judgment against the company.

The takeaway

This lawsuit highlights the importance of transparency and accurate reporting for biotechnology companies, especially during the development of high-profile products like COVID-19 vaccines. The outcome could set a precedent for future shareholder actions against pharmaceutical firms.